纤溶酶原激活物抑制剂1与2型糖尿病及大血管病变  

Relationship of Plasminogen Activator Inhibitor-1 with Patients with Type 2 Diabetes Mellitus and its Macroangiopathy

作　　者：王光亚[1] 张素芬[1] 

机构地区：[1]沧州市中心医院内分泌科,河北沧州061001

出　　处：《医学综述》2007年第24期1972-1973,共2页Medical Recapitulate

基　　金：河北省卫生厅基金资助项目(04058)

摘　　要：纤溶酶原激活物抑制剂1(PAI-1)是一种单链糖蛋白,起抑制纤溶活性的作用。2型糖尿病患者由于高血糖、脂代谢异常、胰岛素抵抗等因素,血浆PAI-1水平升高,纤溶活性下降,易致大血管病变,故降低血浆PAI-1水平可作为防治2型糖尿病及大血管病变的研究方向。文章通过对纤溶酶原激活物抑制剂1的基因、来源、调节因素等多方面加以综述。Plasminogen activator inhibitor-1 （PAl-I） is a single strand glycoprotein,which can in- hibit plasminogen activation. Because of many factors including hyperglucosemia, abnormal lipid rne- tabolism,insulin resistance and so on,Patients with type 2 diabetes had increased level of plasma PAl-1 and decreased activity of fibmlysis, which will result in macroangiopathy. So,decreasing the level of PAI- l can be considered as the study direction in preventing type 2 diabetes and its macroangiopathy.This arti- cle reviews PAl-1 about its gene. souree.reaulatortv factors and so on.

关 键 词：纤溶酶原激活物抑制剂l 2型糖尿病 大血管病变 

分 类 号：R587.1[医药卫生—内分泌]